GTF2E2 and pancreatic adenocarcinoma: We first examined the immune subtypes of the original 15 cancers and found substantial variations in GTF2E2 expression in seven cancers: PAAD across five subtypes; LGG and LUAD, each in four subtypes; GBM in three subtypes; and KIRC, KIRP, and MESO, each in six subtypes (Fig 7A–7G).